| Factor Information | |
|---|---|
| Data ID | 2125 |
| Factor | METs (metabolic equivalents) |
| Description | summarizes the findings of exercise testing before and after PGI2 therapy.METs increased significantly, from 3.7 ± 1.0 to 5.3 ± 1.0 (p = 0.046) |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | treatment and prognosis |
| Objective | In this study, we present the hemodynamic and clinical effects of long-term, continuous PGI2 administration in eight adult patients with CHD-PAH. |
| p Value | 0.046 |
| Conclusion | Summarizes the findings of exercise testing before and after PGI2 therapy.METs increased significantly, from 3.7 ± 1.0 to 5.3 ± 1.0 (p = 0.046) |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 584 |
| CHD Type | isolated CHD |
| CHD Subtype | ASD/TGA |
| Reference | |
|---|---|
| PMID | 23890862 |
| Year | 2013 |
| Title | Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease |
| Sample | ||
|---|---|---|
| Population | Adults | |
| Source | Database | |
| Region | Chicago, United States | |
| Method | retrospectively reviewed | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | One patient had surgical correction of his congenital heart lesion at age 22 months. | |
| Group | after prostacyclin analogs (PGI2) therapy(Treatment) | Baseline(before PGI2 therapy)(Control) |
| Number | 8 | 8 |
| Age | 37 ± 10.5 years | 37 ± 10.5 years |
| Gender (Male: Female) | 2:6 | 2:6 |
| Marker Level | 5.3 ± 1.0 | 3.7 ± 1.0 |
